Literature DB >> 20806381

Standardization of relative cerebral blood volume (rCBV) image maps for ease of both inter- and intrapatient comparisons.

Devyani Bedekar1, Todd Jensen, Kathleen M Schmainda.   

Abstract

Relative cerebral blood volume (rCBV) measured using dynamic susceptibility contrast MRI suffers from interpatient and interstudy variability for the same tissue type. Traditionally, when a more quantitative assessment of rCBV is required, as for comparison across studies and patients, the rCBV values are normalized to the rCBV in a reference region such as normal-appearing white matter. However, this technique of normalization is subjective and time consuming and introduces user-dependent variability. In this study, we demonstrate that a method called standardization, applied to rCBV maps, is an objective means of translating all rCBV values to a consistent scale. This approach reduces interpatient and interstudy variability for the same tissue type, thus enabling easy and accurate visual and quantitative comparison across studies. One caveat to this approach is that it is not appropriate for the evaluation of global changes in blood volume, since systematic differences are removed in the process of standardization. 2010 Wiley-Liss, Inc.

Entities:  

Mesh:

Year:  2010        PMID: 20806381      PMCID: PMC4323176          DOI: 10.1002/mrm.22445

Source DB:  PubMed          Journal:  Magn Reson Med        ISSN: 0740-3194            Impact factor:   4.668


  18 in total

1.  High-grade gliomas and solitary metastases: differentiation by using perfusion and proton spectroscopic MR imaging.

Authors:  Meng Law; Soonmee Cha; Edmond A Knopp; Glyn Johnson; John Arnett; Andrew W Litt
Journal:  Radiology       Date:  2002-03       Impact factor: 11.105

2.  Dynamic, contrast-enhanced perfusion MRI in mouse gliomas: correlation with histopathology.

Authors:  Soonmee Cha; Glyn Johnson; Youssef Zaim Wadghiri; Olivier Jin; Jim Babb; David Zagzag; Daniel H Turnbull
Journal:  Magn Reson Med       Date:  2003-05       Impact factor: 4.668

3.  Low-grade gliomas: dynamic susceptibility-weighted contrast-enhanced perfusion MR imaging--prediction of patient clinical response.

Authors:  Meng Law; Sarah Oh; James S Babb; Edwin Wang; Matilde Inglese; David Zagzag; Edmond A Knopp; Glyn Johnson
Journal:  Radiology       Date:  2006-01-05       Impact factor: 11.105

4.  AZD2171, a pan-VEGF receptor tyrosine kinase inhibitor, normalizes tumor vasculature and alleviates edema in glioblastoma patients.

Authors:  Tracy T Batchelor; A Gregory Sorensen; Emmanuelle di Tomaso; Wei-Ting Zhang; Dan G Duda; Kenneth S Cohen; Kevin R Kozak; Daniel P Cahill; Poe-Jou Chen; Mingwang Zhu; Marek Ancukiewicz; Maciej M Mrugala; Scott Plotkin; Jan Drappatz; David N Louis; Percy Ivy; David T Scadden; Thomas Benner; Jay S Loeffler; Patrick Y Wen; Rakesh K Jain
Journal:  Cancer Cell       Date:  2007-01       Impact factor: 31.743

5.  High microvascular blood volume is associated with high glucose uptake and tumor angiogenesis in human gliomas.

Authors:  H J Aronen; F S Pardo; D N Kennedy; J W Belliveau; S D Packard; D W Hsu; F H Hochberg; A J Fischman; B R Rosen
Journal:  Clin Cancer Res       Date:  2000-06       Impact factor: 12.531

6.  Method for improving the accuracy of quantitative cerebral perfusion imaging.

Authors:  Ken E Sakaie; Wanyong Shin; Kenneth R Curtin; Richard M McCarthy; Ty A Cashen; Timothy J Carroll
Journal:  J Magn Reson Imaging       Date:  2005-05       Impact factor: 4.813

Review 7.  Value of dynamic susceptibility contrast magnetic resonance imaging in the evaluation of intracranial tumors.

Authors:  T Sugahara; Y Korogi; Y Shigematsu; L Liang; K Yoshizumi; M Kitajima; M Takahashi
Journal:  Top Magn Reson Imaging       Date:  1999-04

8.  New variants of a method of MRI scale standardization.

Authors:  L G Nyúl; J K Udupa; X Zhang
Journal:  IEEE Trans Med Imaging       Date:  2000-02       Impact factor: 10.048

9.  Utility of simultaneously acquired gradient-echo and spin-echo cerebral blood volume and morphology maps in brain tumor patients.

Authors:  K M Donahue; H G Krouwer; S D Rand; A P Pathak; C S Marszalkowski; S C Censky; R W Prost
Journal:  Magn Reson Med       Date:  2000-06       Impact factor: 4.668

10.  Dynamic contrast-enhanced T2-weighted MR imaging of recurrent malignant gliomas treated with thalidomide and carboplatin.

Authors:  S Cha; E A Knopp; G Johnson; A Litt; J Glass; M L Gruber; S Lu; D Zagzag
Journal:  AJNR Am J Neuroradiol       Date:  2000-05       Impact factor: 4.966

View more
  38 in total

1.  New similarity search based glioma grading.

Authors:  Katrin Haegler; Martin Wiesmann; Christian Böhm; Jessica Freiherr; Oliver Schnell; Hartmut Brückmann; Jörg-Christian Tonn; Jennifer Linn
Journal:  Neuroradiology       Date:  2011-12-14       Impact factor: 2.804

2.  Dynamic susceptibility contrast MRI measures of relative cerebral blood volume continue to show promise as an early response marker in the setting of bevacizumab treatment.

Authors:  Jerrold L Boxerman; Kathleen M Schmainda; Zheng Zhang; Daniel P Barboriak
Journal:  Neuro Oncol       Date:  2015-09-11       Impact factor: 12.300

3.  Persistent diffusion-restricted lesions in bevacizumab-treated malignant gliomas are associated with improved survival compared with matched controls.

Authors:  S Mong; B M Ellingson; P L Nghiemphu; H J Kim; L Mirsadraei; A Lai; W Yong; T M Zaw; T F Cloughesy; W B Pope
Journal:  AJNR Am J Neuroradiol       Date:  2012-04-26       Impact factor: 3.825

4.  ASFNR recommendations for clinical performance of MR dynamic susceptibility contrast perfusion imaging of the brain.

Authors:  K Welker; J Boxerman; A Kalnin; T Kaufmann; M Shiroishi; M Wintermark
Journal:  AJNR Am J Neuroradiol       Date:  2015-04-23       Impact factor: 3.825

5.  Multisite Concordance of DSC-MRI Analysis for Brain Tumors: Results of a National Cancer Institute Quantitative Imaging Network Collaborative Project.

Authors:  K M Schmainda; M A Prah; S D Rand; Y Liu; B Logan; M Muzi; S D Rane; X Da; Y-F Yen; J Kalpathy-Cramer; T L Chenevert; B Hoff; B Ross; Y Cao; M P Aryal; B Erickson; P Korfiatis; T Dondlinger; L Bell; L Hu; P E Kinahan; C C Quarles
Journal:  AJNR Am J Neuroradiol       Date:  2018-05-24       Impact factor: 3.825

6.  Effects of perfusion on diffusion changes in human brain tumors.

Authors:  Alexander D Cohen; Peter S LaViolette; Melissa Prah; Jennifer Connelly; Mark G Malkin; Scott D Rand; Wade M Mueller; Kathleen M Schmainda
Journal:  J Magn Reson Imaging       Date:  2013-02-06       Impact factor: 4.813

7.  Vascular change measured with independent component analysis of dynamic susceptibility contrast MRI predicts bevacizumab response in high-grade glioma.

Authors:  Peter S LaViolette; Alex D Cohen; Melissa A Prah; Scott D Rand; Jennifer Connelly; Mark G Malkin; Wade M Mueller; Kathleen M Schmainda
Journal:  Neuro Oncol       Date:  2013-02-03       Impact factor: 12.300

8.  Dynamic-susceptibility contrast agent MRI measures of relative cerebral blood volume predict response to bevacizumab in recurrent high-grade glioma.

Authors:  Kathleen M Schmainda; Melissa Prah; Jennifer Connelly; Scott D Rand; Raymond G Hoffman; Wade Mueller; Mark G Malkin
Journal:  Neuro Oncol       Date:  2014-01-15       Impact factor: 12.300

9.  Spatial discrimination of glioblastoma and treatment effect with histologically-validated perfusion and diffusion magnetic resonance imaging metrics.

Authors:  Melissa A Prah; Mona M Al-Gizawiy; Wade M Mueller; Elizabeth J Cochran; Raymond G Hoffmann; Jennifer M Connelly; Kathleen M Schmainda
Journal:  J Neurooncol       Date:  2017-09-12       Impact factor: 4.130

10.  Dynamic susceptibility contrast MRI measures of relative cerebral blood volume as a prognostic marker for overall survival in recurrent glioblastoma: results from the ACRIN 6677/RTOG 0625 multicenter trial.

Authors:  Kathleen M Schmainda; Zheng Zhang; Melissa Prah; Bradley S Snyder; Mark R Gilbert; A Gregory Sorensen; Daniel P Barboriak; Jerrold L Boxerman
Journal:  Neuro Oncol       Date:  2015-02-02       Impact factor: 12.300

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.